TB Vaccines for the World

23-25 May 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 24th May

SESSION 5:
BIOMARKERS

Moderator: Hazel Dockrell (London School of Hygiene & Tropical Medicine, London, UK)

08.30-09.00
‘Towards correlates of protection for use in TB vaccine trials’
Hazel Dockrell (London School of Hygiene & Tropical Medicine, London, UK)

09.00-09.25
‘Are we measuring the right immune markers in vaccine trials’
Willem Hanekom (South African TB Vaccine Initiative, University of Cape Town, South Africa)

09.25-09.50
‘TB antigen discovery and TB biomarker discovery’
Tom H.M. Ottenhoff (Leiden University, Leiden, The Netherlands)

09.50-10.15
‘Host correlates of risk of TB disease, following routine vaccination of infants with BCG’
Helen Fletcher (University of Oxford, Oxford, UK)

10.15-10.45
‘Metabolomics in TB’
Delphi Chatterjee (Colorado State University, Fort Collins, Colorado, USA)

10.45-11.15
Coffee Break

SESSION 6:
ADJUVANTS

Moderator: Ian M. Orme (Colorado State University, Colorado, USA)

11.15-11.45
‘Non-living TB vaccines and TB adjuvants’
Steve Reed (IDRI, Seattle, Washington, USA)

11.45-12.15
‘High mobility group box 1 (HMGB1) as an adjuvant for tuberculosis subunit vaccines’
Ajay Grover, Jolynn Troudt and Angelo A. Izzo (Colorado State University, Fort Collins, Colorado, USA)

12.15-13.30
Lunch Break

SESSION 7:
TB VACCINES

Moderator: Jeff Ulmer (Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA)

13.30-13.50
‘Technologies for the discovery and development of new and improved vaccines’
Jeff Ulmer (Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA)

13.50-14.10
‘Novel BCG vaccine studies’
Sheldon Morris (CBER/FDA, Rockville, Maryland, USA)

14.10-14.30
‘A spoonful of BCG: Determining the immune response to oral BCG vaccination’
Lindsay Ancelet, Frank Aldwell, Fenella Rich and Joanna Kirman (Malaghan Institute of Medical Research, Wellington, New Zealand)

14.30-14.50
‘A novel therapeutic vaccine (HVJ-Envelope/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model’
M. Okada, Y. Kita, N. kanamaru, S. Hashimoto, H. Nakatani, S. Nishimatsu, Y. Ishida, H. Hayashi, T. Nakajima, Y. Kaneda, P. Saunderson, E.V. Tan, E. Dela Cruz and D. McMurray (National Hospital Organization, Osaka, Japan)

14.50-15.10
‘Evaluation of an in silico derived RD protein based multi-epitope therapeutic vaccine in mouse model of tuberculosis’
Indu Verma, Javaid Ahmad Sheikh and Dheeraj Gupta (PGIMER, Chandigarh, India)

15.10-15.40
Tea Break

SESSION 7:
CONTINUED

15.40-16.00
‘Safety and immunogenicity of novel tuberculosis vaccine AERAS-402 in healthy infants previously vaccinated with BCG’
Michele Tameris et al. (South African TB Vaccine Initiative, University of Cape Town, South Africa)

16.00-16.20
‘Increasing the vaccine potential of M. bovis BCG using a combination with plasmid DNA encoding the mycolyl-transferase AG85A’
Kris Huygen, Nicolas Bruffaerts and Marta Romano (WIV-ISP, Brussels, Belgium)

16.20-16.40
‘Evaluating the impact of intradermal, intramuscular, and inhaled delivery of a new TB vaccine, MVA85A’
Joel Meyer, I. Satti, S. Harris, H. Bettinson, R. Antorbus, R. Lopez Ramon and H. McShane (University of Oxford, Oxford, UK)

SESSION 8:
ALL YOU NEED TO KNOW ABOUT BCG

Moderator: David N. McMurray (Texas A&M University, College Station, Texas, USA)

16.40-16.55
‘BCG Yesterday: Introduction & BCG history viewpoint’
Micha Roumiantzeff (Independent Consultant, Lyon, France)

16.55-17.10
‘Practical challenges in todays and tomorrows BCG production’
Peter Hubrechts (SSI, Copenhagen, Denmark)

17.10-17.25
‘BCG Today: Immune responses to different BCG vaccine strains’
Nigel Curtis (The University of Melbourne, Parkville, Victoria, Australia)

17.25-17.40
‘BCG Today: WHO Recommendations to assure the quality, safety and efficacy of BCG vaccines’
Mei Mei Ho (NIBSC-HPA, South Mimms, Potters Bar, UK)

17.40-17.50
‘BCG Today: Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guerin (BCG) vaccines from different sources’
Speaker to be confirmed

17.50-18.15
‘BCG Tomorrow: Future developments for BCG vaccines’
Leander Grode (Vakzine Projekt Management GmbH (VPM), Hannover, Germany)

 

TBV 2012 Delegates

Login details will be supplied after you have registered for the event.


TBV 2012 Sponsors

  • Centers for Disease Control and Prevention
  • Infectious Disease Research Institute
  • Intercell Smart Vaccines
  • Vakzine Project Management

TBV 2012 Downloads

TBV 2012 Leaflet

TBV 2012 Mailing List

Name
E-mail Address
What is 1+4-2?